HemaCare Corporation Stock

HEMA

US4234981045

Healthcare Facilities & Services

Delayed OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		+0.08%	+0.24%

20-06-02	HemaCare Corporation Adds GMPrime Cryopreserved Leukopak to its GMP Product Portfolio	CI
20-01-21	MicroMedicine and HemaCare Announces Cooperative Efforts to Improve Cell Therapy Starting Materials	CI

Valuation : HemaCare Corporation

Market Cap	346M 298M 281M 256M 478M 32.66B 482M 3.33B 1.29B 16.7B 1.3B 1.27B 54.85B	P/E 2017	8.18x	P/E 2018	27.6x
Enterprise Value	336M 290M 273M 249M 465M 31.72B 468M 3.23B 1.25B 16.22B 1.26B 1.23B 53.28B	EV / Sales 2017	1.29x	EV / Sales 2018	4.03x
Free-Float	94.17%	Yield 2017 *	-	Yield 2018	-

* Estimated data More valuation ratios

Latest news : HemaCare Corporation

20-06-02	HemaCare Corporation Adds GMPrime Cryopreserved Leukopak to its GMP Product Portfolio	CI
20-01-21	MicroMedicine and HemaCare Announces Cooperative Efforts to Improve Cell Therapy Starting Materials	CI
20-01-02	Charles River Laboratories International, Inc. completed the acquisition of HemaCare Corporation.	CI
19-12-15	Charles River Laboratories International, Inc. entered into a definitive agreement to acquire HemaCare Corporation for approximately $380 million.	CI
19-11-19	HemaCare Expands Its Product Portfolio with GMPrime™ Bone Marrow Aspirate	CI
19-08-27	HemaCare Corporation and Vital River Partner to Provide Human-Derived Biological Material to China	CI
19-08-20	Hemacare Corporation Reports Earnings Results for the Half Year Ended June 30, 2019	CI
19-03-26	HemaCare Corporation Reports Earnings Results for the Year Ended December 31, 2018	CI
18-12-19	HemaCare Corporation announced that it has received $4.999999 million in funding from OBF Investments LLP	CI
18-12-06	HemaCare Corporation Moves its Global Headquarters to Northridge, California	CI
18-11-14	HemaCare Corporation Provides Starting Material for Three FDA Approved Cellular Therapies	CI
18-08-21	HemaCare Corporation Reports Unaudited Earnings Results for the Six Months Ended June 30, 2018	CI
18-07-17	HemaCare Corporation Announces Executive Appointments	CI

More news

Press Releases : HemaCare Corporation

19-12-16

HEMACARE ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of HEMA and Encourages Investors to Contact the Firm

More press releases

Managers and Directors : HemaCare Corporation

Manager	Title	Age	Since
Colin S. Dunn CEO	Chief Executive Officer	-	-
Samira Amini DFI	Director of Finance/CFO	-	-
Maria Pia Muniz COO	Chief Operating Officer	-	2002-12-31

Director	Title	Age	Since
Colin S. Dunn BRD	Director/Board Member	-	-
Samira Amini BRD	Director/Board Member	-	-
Emily Nekimken BRD	Director/Board Member	-	-

More insiders

Other Healthcare Facilities & Services

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
HEMACARE CORPORATION	-.--%	+0.08%	-	-	346M
CVS HEALTH CORPORATION	+0.55%	+5.08%	+33.17%	+48.82%	124B
HCA HEALTHCARE, INC.	+2.18%	-2.07%	+0.74%	+49.73%	87.05B
FRESENIUS SE & CO. KGAA	-3.55%	-1.06%	-1.39%	+55.76%	29.19B
QUEST DIAGNOSTICS INCORPORATED	-0.33%	-1.80%	+33.81%	+88.77%	26.58B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	-0.26%	-4.48%	-4.92%	-5.03%	21.51B
TENET HEALTHCARE CORPORATION	+1.96%	-1.42%	+41.21%	+244.39%	20.82B
REDE D'OR SÃO LUIZ S.A.	+1.00%	+6.26%	-3.99%	+28.93%	15.85B
FRESENIUS MEDICAL CARE AG	-1.93%	-3.81%	-7.88%	-13.41%	12.09B
DAVITA INC.	+1.35%	+1.35%	+33.33%	+87.58%	11.44B
Average	+0.12%	-1.26%	+13.79%	+65.06%	34.92B
Weighted average by Cap.	+0.55%	-0.99%	+17.26%	+59.23%

See all sector performances

Charles River Laboratories Cell Solutions, Inc. is a cell sourcing provider for developers of cell therapies and basic research. The Company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. It offers a comprehensive and integrated portfolio of drug development products and services available from a single global provider, spanning the continuum from early research to the support of marketed products. Its products and services include Research Models & Services, Discovery Services Safety Assessment, Laboratory Sciences, Cell and Gene Therapy CDMO Solutions, Biologics Testing Solutions, Avian Vaccine Services, QC Microbial Solutions, Scientific & Regulatory Advisory Services, and Scientific Staffing, Training & Operations Support.

Employees

Sector

Healthcare Facilities & Services

More about the company

Rankings

Rankings

Currency / Forex

Commodities

Cryptocurrencies

Interest Rates

Stock Market
Stocks
HEMA Stock

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

	2017	2018
Net sales	20.21M 17.44M 16.43M 14.97M 27.97M 1.91B 28.18M 194M 75.47M 976M 75.9M 74.24M 3.21B	28.51M 24.59M 23.17M 21.11M 39.45M 2.69B 39.75M 274M 106M 1.38B 107M 105M 4.52B
Net income	4.43M 3.82M 3.6M 3.28M 6.13M 419M 6.18M 42.64M 16.55M 214M 16.64M 16.28M 703M	4.52M 3.9M 3.67M 3.34M 6.25M 427M 6.3M 43.45M 16.86M 218M 16.96M 16.59M 716M
Net Debt	-9.06M -7.82M -7.36M -6.71M -12.54M -856M -12.63M -87.16M -33.83M -438M -34.02M -33.27M -1.44B	-9.9M -8.54M -8.04M -7.33M -13.7M -935M -13.8M -95.22M -36.96M -478M -37.16M -36.35M -1.57B

HemaCare Corporation Stock

Stocks

HEMA

US4234981045

Healthcare Facilities & Services

Valuation : HemaCare Corporation

Latest news : HemaCare Corporation

Press Releases : HemaCare Corporation

Managers and Directors : HemaCare Corporation

Other Healthcare Facilities & Services

Financials

Company Profile